News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nuvilex Advances Company Toward Future Clinical Treatments Through Successful Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes



11/8/2013 9:31:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SILVER SPRING, Md., Nov. 8, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX) -- On Thursday, November 7, 2013, the Financial Industry Regulatory Authority, Inc. ("FINRA") halted trading in all OTC Equity Securities pursuant to FINRA Rule 6440(a)(3). The Management of Nuvilex, Inc. later learned of technical connectivity problems the OTC Markets experienced after FINRA required the markets to be shut down. It appears the decision to prevent trading for much of the day's session resulted in a great deal of confusion for those who trade on this Exchange. Because of this confusion as well as calls by our shareholders inquiring about the Company and the press release, Nuvilex's Management has chosen to re-release the company's important news regarding our diabetes acquisition.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Nuvilex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES